Lynn Seely, Myovant CEO (Myovant)

My­ovant read­ies NDA #3 as re­l­u­golix sails to its 5th pos­i­tive PhI­II — this time in en­dometrio­sis

My­ovant $MY­OV is on a roll.

In the last few days the biotech spawned on Vivek Ra­maswamy’s Roivant plat­form has post­ed a pos­i­tive read­out on prostate can­cer for their drug re­l­u­golix, fol­lowed by a pri­or­i­ty re­view re­ward from the FDA. It’s got an­oth­er NDA on uter­ine fi­broids lined up. And now it has post­ed its sec­ond round of promis­ing piv­otal re­sults for en­dometrio­sis, set­ting the stage for NDA num­ber 3.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.